相关临床试验
6
0 进行中
药物批准
0
批准总数
监管机构
0
监管机构数
成立时间
N/A
暂无试验阶段数据
已完成
1
16.7%
招募中
2
33.3%
终止
1
16.7%
Unknown
2
33.3%
暂无批准数据
- Caris Life Sciences will present seven studies at the IASLC 2026 World Conference on Lung Cancer in Seoul, South Korea, from September 12–15, 2026, spanning two mini oral presentations, one Poster Tour, and four posters. - A 39,124-sample NSCLC analysis found PRMT5-high/MTAP-deleted tumors had the shortest overall survival and fewer CD8+ T-cells, suggesting a less favorable immune microenvironment. - A 43,261-sample study identified race- and ethnicity-associated differences in tumor genomics and immunotherapy outcomes, with non-Hispanic Black patients achieving longer survival despite more resistance alterations. - Transcriptomic analysis of 386 mesothelioma samples identified three distinct clusters where chemotherapy (with or without bevacizumab) outperformed immune checkpoint inhibitors in two clusters.
- A genomic analysis of 787 esophageal cancer patients found KMT2 mutations were markedly more frequent in esophageal squamous cell carcinoma (20.8%) than in esophageal adenocarcinoma (4.3%). - KMT2-mutant esophageal adenocarcinoma patients had significantly longer immune-related overall survival on immunotherapy (21.42 vs 13.42 months; HR 0.66, P=0.004), but no such benefit emerged in ESCC. - KMT2 mutations were strongly associated with microsatellite instability-high status and higher tumor mutational burden in both histologies, supporting their role as an immunotherapy biomarker. - The findings suggest KMT2 mutations may help guide immune checkpoint inhibitor selection in esophageal adenocarcinoma, though prospective validation is needed.
- The American Society for Biochemistry and Molecular Biology (ASBMB) has appointed new members across nine key committees, with terms beginning July 1. - Notable leadership transitions include Mark Whitmer of Bristol Myers Squibb becoming incoming Membership Committee chair and Juanita Limas of Eli Lilly as incoming WiBMB chair. - The society expanded professional membership eligibility to molecular life scientists across all sectors, including academia, government, and industry. - ASBMB President emphasizes building connections between fundamental research and translational application to accelerate scientific progress.
- Caris Life Sciences reported a record second quarter with approximately 59,200 clinical cases, up more than 12% sequentially, reflecting sustained demand for its molecular profiling services. - Revenue jumped 45% year-over-year to $263.7 million, while net loss attributable to shareholders narrowed 99% to $637,000 from $517.2 million. - The company now projects full-year 2026 revenue of $1.03 billion to $1.04 billion, driven by the launch of Caris Detect, an AI-enabled multi-cancer early detection blood test. - Caris Detect uses artificial intelligence and ultra-deep sequencing to analyze the entire genome, with plans to convert early cancer signals into personalized immune targets through a "Mutational Cleanse."
- Caris Life Sciences' Board of Directors has authorized a share repurchase program for up to $100 million of the company's outstanding common stock. - The repurchase program has no expiration date and may be executed through open market purchases, privately negotiated transactions, or Rule 10b5-1 trading plans. - The timing and amount of repurchases will depend on market conditions, stock price, financial performance, and other business factors at the company's discretion. - Caris Life Sciences is a precision medicine pioneer leveraging comprehensive molecular profiling and AI to develop diagnostic solutions for early detection, therapy selection, and drug development.
